Rituximab in children with B-NHL on top of BFM95 protocol - PowerPoint PPT Presentation

maia
rituximab in children with b nhl on top of bfm95 protocol n.
Skip this Video
Loading SlideShow in 5 Seconds..
Rituximab in children with B-NHL on top of BFM95 protocol PowerPoint Presentation
Download Presentation
Rituximab in children with B-NHL on top of BFM95 protocol

play fullscreen
1 / 16
Download Presentation
Rituximab in children with B-NHL on top of BFM95 protocol
146 Views
Download Presentation

Rituximab in children with B-NHL on top of BFM95 protocol

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Rituximab in children with B-NHL on top of BFM95 protocol Paediatric Oncology and Haematology Research Institute N.N.Blokhin Russian Cancer Research Center Moscow Т.Т.Valiev, A.V.Popa, G.L.Mentkevich

  2. Results of multicenter studies on III/IV stages childhood B-NHL

  3. EFS in pediatric pts with B-NHL in Russia (2004) Вероятность Р=0,035 годы • Е.В.Самочатова, Н.В.Мякова и др. Гематология и трансфузиология»,2004,№1,с.3;

  4. Literature data are limited • 3-year EFS in children with B-NHL III/IV stages treated by FAB/LMB96 (R+) - 95% FAB/LMB96 (R-) – 84% • Goldman , ASH, Abstract No 2702, 2011

  5. Overall response rate 41% • Rituximab toxicity (grade III/IV) -General condition 15% -Fatigue 13% -ALT/AST 8% -Anaphylaxis 7% -Infection 3%

  6. B-NHL-BFM 95 protocol modification(Italian experience)(A.Rosolen, M.Pillon, L.Mussolin 2012)

  7. Modified B-NHL BFM95 protocol(rituximab regimen) 2007-2010 4 risk group AA BB CC AA BB CC 3 risk group АА ВВ СС АА ВВ

  8. Patients characteristics

  9. Results of modified B-NHL BFM95 protocol(rituximab regimen) EFS= 94,4+/-4,3% R+ (n=28) (median73,7+/-4,3 мo) EFS= 74,8+/-9,7% R- (n=25) (median 119,8+/-8,7 мo)

  10. EFS in group with M1 – 91,9% • EFS in group without M1 – 92,5%

  11. Modified B-NHL BFM95(rituximab regimen, block reduction) 2010-… 4 risk group AA BB CC AA BB 3 risk group АА ВВ СС АА ВВ

  12. Comparative analysis of block reduction and standard block therapy with rituximab

  13. Treatment failure for B-NHL BFM95 protocol (rituximab regimen)

  14. Treatment toxicity for B-NHL BFM95 protocol (rituximab regimen)

  15. Conclusions • Rituximab with B-NHL BFM95 protocol as a first-line treatment in children with B-NHL(unfavorable stages and risk groups) increased EFS significantly • Toxicity profile of rituximab regimen was comparable with standard B-NHL BFM95 protocol • It is possible to reduce block number for pts with B-NHL R4 with early complete response from six to five

  16. Thank Youfor attention!